Abiopharma

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF")

New Form 4 - Anixa Biosciences Inc Filed: 2025-07-31 AccNo: 0001641172-25-021679 Size: 4 KB

AIM ImmunoTech Announces Closing of $8.0 Million Public Offering

New Form 10-Q - Vanda Pharmaceuticals Inc. Filed: 2025-07-31 AccNo: 0001628280-25-036861 Size: 6 MB

New Form 8-K - SUPERNUS PHARMACEUTICALS, INC. Filed: 2025-07-31 AccNo: 0001104659-25-072506 Size: 449 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form NT 20-F - Zhong Yuan Bio-Technology Holdings Ltd Filed: 2025-07-31 AccNo: 0001079973-25-001202 Size: 16 KB

New Form 10-Q - Vericel Corp Filed: 2025-07-31 AccNo: 0001628280-25-036859 Size: 6 MB

New Form 8-K - Glucotrack, Inc. Filed: 2025-07-31 AccNo: 0001493152-25-011509 Size: 237 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - bioAffinity Technologies, Inc. Filed: 2025-07-31 AccNo: 0001641172-25-021677 Size: 317 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results

UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics

New Form 4 - Silence Therapeutics plc Filed: 2025-07-31 AccNo: 0001104659-25-072499 Size: 8 KB